Literature DB >> 22554391

Piecing together the puzzle of progression and mortality in Parkinson's disease.

Connie Marras1, David Oakes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22554391      PMCID： PMC3630746          DOI： 10.1111/j.1365-2125.2012.04315.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  10 in total

1.  Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.

Authors:  P T Donnan; D T Steinke; C Stubbings; P G Davey; T M MacDonald
Journal:  Neurology       Date:  2000-12-26       Impact factor: 9.910

2.  Selegiline and Parkinson's disease: it's déjà vu-again.

Authors:  J W Langston; C M Tanner
Journal:  Neurology       Date:  2000-12-26       Impact factor: 9.910

3.  Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.

Authors:  Thuy C Vu; John G Nutt; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

4.  Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.

Authors:  Thuy C Vu; John G Nutt; Nicholas H G Holford
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

Review 5.  Prognostic factors for the progression of Parkinson's disease: a systematic review.

Authors:  Bart Post; Maruschka P Merkus; Rob J de Haan; Johannes D Speelman
Journal:  Mov Disord       Date:  2007-10-15       Impact factor: 10.338

Review 6.  Predicting motor decline and disability in Parkinson disease: a systematic review.

Authors:  Connie Marras; Paula Rochon; Anthony E Lang
Journal:  Arch Neurol       Date:  2002-11

7.  Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.

Authors:  A Churchyard; C J Mathias; P Boonkongchuen; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

8.  Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

Authors:  A J Lees
Journal:  BMJ       Date:  1995-12-16

9.  Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.

Authors:  C W Olanow; V V Myllylä; K A Sotaniemi; J P Larsen; S Pålhagen; H Przuntek; E H Heinonen; O Kilkku; R Lammintausta; O Mäki-Ikola; U K Rinne
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

10.  Mortality in people taking selegiline: observational study.

Authors:  M Thorogood; B Armstrong; T Nichols; J Hollowell
Journal:  BMJ       Date:  1998-07-25
  10 in total
  1 in total

1.  Authors' response to Marras and Oakes, 'Piecing together the puzzle of progression and mortality in Parkinson's disease'.

Authors:  Nicholas H G Holford; Thuy C Vu; John G Nutt
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.